OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).
OBM Neurobiology publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.
Publication Speed (median values for papers published in 2023): Submission to First Decision: 7.5 weeks; Submission to Acceptance: 15.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)
Neurogenetic, Epigenetic and Molecular Neurobiological Correlates of Addiction Neuroscience and Personalized Therapies
Submission Deadline: August 15, 2024 (Open) Submit Now
Kenneth Blum, PhD, Professor, genetic fellowship -1978- institute of behavioral genetics colorado university -boulder
Division of Addiction Research & Education, Center for Sports and Mental Health, Western University of Health Sciences, Pomona, CA 91766, USA
Research Interests: Genetics of alcoholism; Neuropsychiatry and genetics; Nutritional genetics; Pharmacogenetics
About This Topic
Addiction neuroscience is a multidisciplinary approach to treating substance and non-substance (such as eating disorders) addictive behaviors. Researchers in this field aim to understand the neural mechanisms underlying this disease. Over the past 60 or more years, substance use disorder (SUD) research has increased significantly, as has our understanding of the neural and genetic mechanisms of addiction. New methodologies have been developed (both clinical and pre-clinical) to assess molecular and neurochemical changes in neuronal systems. New advancements have revealed neurogenetic and epigenetic processes by which molecular, neurobiological, and social spiritual factors increase vulnerability and resilience to these behaviors. In the case of SUD, it is important to remember that there many DNA pre-addiction antecedents and additional unwanted negative insults due to epigenetics.
The gold standard of care for the so called opioid deficiency is to administer opioids to treat opioid dependence. One cornerstone of addiction liability, for example, an individual’s inability to replace short-term rewards with more beneficial long-term rewards can involve neurological and behavioral disruption. Knowledge of the combinative role of genes and environment (epigenetics) can help sway unwanted substances and behavioral addictions. Overall well-being involves numerous neurotransmitters and second messengers. Their intricate interactions regulate the release of dopamine at post-neuronal sites, such as the Nucleus Accumbens (commonly referred to as the brain’s reward center).
It is our responsibility as scientists and clinicians to focus on novel ways to combat drug-induced dopamine dysregulation and promote the functional balance of dopamine in the brain. Albeit, using powerful opioids to reduce harm, this premise to induce “dopamine homeostasis” can be accomplished via nonpharmaceutical non-addictive and safer interventions including neuromodulation, nutraceuticals as well as cognitive and mindfulness therapies. These therapies should include genetic addiction risk testing and personalized genetic based preventive and tertiary approaches.
This special issue welcomes all types of articles that contribute to our knowledge related to both substance and non-substance behavioral addictions.
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (email@example.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!